Expression analysis of the PMP22 gene in glioma and osteogenic sarcoma cell lines

Hühne, Kathrin; Park, Oksoon; Liehr, Thomas; Rautenstrauss, Bernd

doi:10.1002/(sici)1097-4547(19991201)58:5<624::aid-jnr3>3.0.co;2-n

Cited by 22 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Next to its structural role, PMP22 has important functions in cell growth control in non-neural tissues. We [32] and others [33] have previously reported upregulation of PMP22 expression in osteosarcoma tumours and cell lines. Since then, increased PMP22 expression has also been noted in invasive versus non-invasive mammary carcinoma cell lines [34], in (pre)malignant lesions versus normal pancreatic tissue [35], and in proliferative versus secretory phase endometrium [36].…”

Section: Discussionmentioning

confidence: 61%

Identification of Novel Candidate Oncogenes in Chromosome Region 17p11.2-p12 in Human Osteosarcoma

Both

Bras

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

Osteosarcoma is the most common primary malignancy of bone. The tumours are characterized by high genomic instability, including the occurrence of multiple regions of amplifications and deletions. Chromosome region 17p11.2–p12 is amplified in about 25% of cases. In previous studies, COPS3 and PMP22 have been identified as candidate oncogenes in this region. Considering the complexity and variation of the amplification profiles for this segment, the involvement of additional causative oncogenes is to be expected. The aim of the present investigation is to identify novel candidate oncogenes in 17p11.2–p12. We selected 26 of in total 85 osteosarcoma samples (31%) with amplification events in 17p11.2–p12, using quantitative PCR for 8 marker genes. These were subjected to high-resolution SNP array analysis and subsequent GISTIC analysis to identify the most significantly amplified regions. Two major amplification peaks were found in the 17p11.2–p12 region. Overexpression as a consequence of gene amplification is a major mechanism for oncogene activation in tumours. Therefore, to identify the causative oncogenes, we next determined expression levels of all genes within the two segments using expression array data that could be generated for 20 of the selected samples. We identified 11 genes that were overexpressed through amplification in at least 50% of cases. Nine of these, c17orf39, RICH2, c17orf45, TOP3A, COPS3, SHMT1, PRPSAP2, PMP22, and RASD1, demonstrated a significant association between copy number and expression level. We conclude that these genes, including COPS3 and PMP22, are candidate oncogenes in 17p11.2–p12 of importance in osteosarcoma tumourigenesis.

show abstract

Section: Discussionmentioning

confidence: 61%

Identification of Novel Candidate Oncogenes in Chromosome Region 17p11.2-p12 in Human Osteosarcoma

Both

Bras

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…However, there are also reports connecting PMP22 to cancer. For instance, the PMP22 gene was found to be amplified in two glioblastoma cell lines and an unusual transcript was found in the cells [29], PMP22 mRNA was higher in pancreatic adenocarcinomas than in normal tissue and was detected in cell lines [30], and high PMP22 mRNA in tumors correlated to poorer survival of breast cancer patients [31]. When it comes to cellular effects, mRNA expression has primarily been shown to be inversely correlated to cell growth [18,32-34] and overexpression of PMP22 leads to delayed G0/G1 to S-phase transition in Schwann cells [35].…”

Section: Discussionmentioning

confidence: 99%

Regulation of PMP22 mRNA by G3BP1 affects cell proliferation in breast cancer cells

2013

View full text Add to dashboard Cite

BackgroundRegulation of mRNAs is one way to control protein levels and thereby important cellular processes such as growth, invasion and apoptosis. G3BPs constitute a family of mRNA-binding proteins, shown to be overexpressed in several cancer types, including breast, colon and pancreas cancer. G3BP has been reported to both stabilize and induce degradation of specific mRNAs.ResultsHere, we show that G3BP1, but not G3BP2, supports proliferation of several breast cancer cell lines. Global gene expression analyses of G3BP1- and G3BP2-depleted cells indicate that primarily G3BP1, and much less G3BP2, influences mRNA expression levels. Peripheral myelin protein 22 (PMP22) was one gene that was significantly influenced by G3BP1 depletion which led to a 2–3 fold increased expression. Depletion of PMP22 resulted in increased proliferation and the G3BP1-mediated effect on proliferation was not seen upon PMP22-depletion.ConclusionsThis indicates a novel role for G3BP1 in the regulation of cell proliferation in breast cancer cells, perhaps via a regulatory effect on PMP22 expression.

show abstract

“…Abnormalities in PMP22 can lead to various peripheral neuropathies [14]. Increased PMP22 expression was found in other pre-malignant or malignant tissues, like pancreatic tissues [15], osteosarcoma, and glioblastoma tissues [16,17]. However, little is known about the functions of PMP22 in human cancer.…”

Section: Discussionmentioning

confidence: 99%

Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients

et al. 2010

View full text Add to dashboard Cite

BackgroundGene expression of peripheral myelin protein 22 (PMP22) and the epithelial membrane proteins (EMPs) was found to be differentially expressed in invasive and non-invasive breast cell lines in a previous study. We want to evaluate the prognostic impact of the expression of these genes on breast cancer.MethodsIn a retrospective multicenter study, gene expression of PMP22 and the EMPs was measured in 249 primary breast tumors by real-time PCR. Results were statistically analyzed together with clinical data.ResultsIn univariable Cox regression analyses PMP22 and the EMPs were not associated with disease-free survival or tumor-related mortality. However, multivariable Cox regression revealed that patients with higher than median PMP22 gene expression have a 3.47 times higher risk to die of cancer compared to patients with equal values on clinical covariables but lower PMP22 expression. They also have a 1.77 times higher risk to relapse than those with lower PMP22 expression. The proportion of explained variation in overall survival due to PMP22 gene expression was 6.5% and thus PMP22 contributes equally to prognosis of overall survival as nodal status and estrogen receptor status. Cross validation demonstrates that 5-years survival rates can be refined by incorporating PMP22 into the prediction model.ConclusionsPMP22 gene expression is a novel independent prognostic factor for disease-free survival and overall survival for breast cancer patients. Including it into a model with established prognostic factors will increase the accuracy of prognosis.

show abstract

Expression analysis of the PMP22 gene in glioma and osteogenic sarcoma cell lines

Cited by 22 publications

References 31 publications

Identification of Novel Candidate Oncogenes in Chromosome Region 17p11.2-p12 in Human Osteosarcoma

Identification of Novel Candidate Oncogenes in Chromosome Region 17p11.2-p12 in Human Osteosarcoma

Regulation of PMP22 mRNA by G3BP1 affects cell proliferation in breast cancer cells

Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients

Contact Info

Product

Resources

About